Your resource for web content, online publishing
and the distribution of digital products.
S M T W T F S
 
 
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
 
21
 
22
 
23
 
24
 
25
 
26
 
27
 
28
 
29
 
30
 
31
 
 

Estimate suggests Accolade may outperform with a potential 320% upside

DATE POSTED:January 9, 2025
Estimate suggests Accolade may outperform with a potential 320% upside

Accolade Inc (ACCD) is scheduled to announce its Q3 2025 earnings on January 9, 2025. According to a GuruFocus article, analysts estimate the company will report revenue of $106.00 million and an earnings loss of -$0.32 per share for the quarter. For the full year 2025, revenue is estimated at $465.38 million, with expected earnings of -$0.92 per share.

Accolade Inc to report Q3 earnings on January 9

Over the past 90 days, revenue projections for Accolade Inc have declined from $469.26 million to $465.38 million for the full year 2025, and from $526.23 million to $524.23 million for 2026. Conversely, earnings forecasts improved, with estimates rising from -$0.95 per share to -$0.92 for 2025, and from -$0.86 to -$0.83 for 2026.

In the previous quarter ending August 31, 2024, Accolade reported revenue of $106.36 million, exceeding analysts’ expectations of $105.01 million by 1.28%. The company’s actual earnings were -$0.30 per share, beating expectations of -$0.44 per share by 32.28%. Following this report, Accolade’s stock increased by 1.76% in a single day.

How Accolade stock pulled off a 105% jump

Price targets and recommendations

According to 12 analysts, the average price target for Accolade Inc is $7.17, with a high estimate of $9.50 and a low estimate of $5.00. This average target suggests an upside potential of 114.15% from the current stock price of $3.35. Additionally, GuruFocus estimates the company’s GF Value at $14.10, indicating an upside of 320.90% from the same current price.

The consensus recommendation from 14 brokerage firms highlights an average rating of 1.8 for Accolade Inc, reflecting an “Outperform” status. The rating scale ranges from 1 (Strong Buy) to 5 (Sell).

  • Assess updates on member retention rates and growth in Accolade’s user base as indicators of sustainable revenue streams.
  • Look for signs of success in cross-selling services, such as bundling primary care and advocacy to boost per-customer revenue.
  • Consider whether Accolade may pursue strategic acquisitions to enhance capabilities and accelerate its market penetration.
  • Pay attention to management’s guidance on improving cash flow, a critical factor for long-term financial health.
  • Evaluate how Accolade aligns with evolving healthcare trends, such as digital solutions and personalized care models.
  • Be alert for commentary on the impact of healthcare regulations or incentives on Accolade’s business model.
  • Track updates on Accolade’s AI-driven tools and their role in driving efficiency and member satisfaction.
  • Compare Accolade’s performance and strategic moves with competitors to gauge its relative market positioning.

Disclaimer: The content of this article is for informational purposes only and should not be construed as investment advice. We do not endorse any specific investment strategies or make recommendations regarding the purchase or sale of any securities.

Featured image credit: Sonia Dauer/Unsplash